BioAge Labs (BIOA) FCF Margin (2025 - 2026)
BioAge Labs' (BIOA) quarterly FCF Margin came in at 799.18% in Q2 2026, up 3531.0% year-over-year from 22.01% in Q2 2025, and up 7.97% quarter-over-quarter from 868.4% in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) FCF Margin (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed FCF Margin across 2 years of filings, most recently posting 799.18% for Q2 2026.
- In Q2 2026, FCF Margin rose 3531.0% year-over-year to 799.18%; the TTM figure through Jun 2026 stood at 850.69% (up 65894.0% YoY), while the FY2025 annual figure was 915.46%, changed N/A from the prior year.
- FCF Margin came in at 799.18% for Q2 2026 at BioAge Labs, up from 868.4% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 782.18% in Q3 2025 to a low of 1225.98% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -18,629.40% |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn | -799.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -799.18% |
| Mar 31, 2026 | -868.40% |
| Dec 31, 2025 | -921.47% |
| Sep 30, 2025 | -782.18% |
| Jun 30, 2025 | -834.49% |
| Mar 31, 2025 | -1,225.98% |